• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nemaura touts data from home-use study of wearable glucose monitor

August 1, 2018 By Sarah Faulkner

NemauraNemaura Medical (NSDQ:NMRD) said today that it launched a study of its wearable glucose monitor in the hopes of winning regulatory approval in the U.S.

The England-based company touted positive interim data from the study, focusing on the at-home use of the sugarBeat device.

The company’s interim results included findings from 25 patients with either Type 1 or Type 2 diabetes who wore the sugarBeat product for one or two non-consecutive days. Each participant also recorded up to five blood glucose readings via finger-pricks per day.

Researchers in Nemaura’s study found that data from the sugarBeat product compared favorably with data gleaned from commercial continuous glucose monitors.

The company’s U.S. study is slated to enroll 75 people who will wear the device over a 7-day period. Nemaura said it expects to finish the study and submit an application to the FDA in the first quarter of 2019.

The company also noted that it anticipates winning CE Mark approval for its sugarBeat device in the coming months.

NMRD shares were trading at $2.76 apiece in mid-afternoon activity today, up 19.8%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diabetes, Featured, Patient Monitoring, Wall Street Beat Tagged With: Nemaura Medical

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS